Clinical data | |
---|---|
Pronunciation | A va PRI ti nib |
Trade names | Ayvakit, Ayvakyt |
Other names | BLU-285, BLU285 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620013 |
License data | |
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor[1] |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C26H27FN10 |
Molar mass | 498.570 g·mol−1 |
3D model (JSmol) | |
| |
|
Avapritinib, sold under the brand name Ayvakit, is a medication used to treat systemic mastocytosis and gastrointestinal stromal tumor (GIST).[2] In GIST it is used for cases with a platelet-derived growth factor receptor A (PDGFRA) exon 18 mutation.[2] It is taken by mouth.[2]
Common side effects nausea, tiredness, low red blood cells, swelling, high bilirubin, diarrhea, and forgetfulness.[1] Other side effects may include pleural effusion and intracranial bleeding.[2][1] Use in pregnancy may harm the baby.[2] It is a tyrosine kinase inhibitor that blocks the activity of PDGFRA.[1]
Avapritinib was approved for medical use in the United States and Europe in 2020.[2][1] In the United Kingdom a month costs the NHS about £26,700 as of 2021.[3] This amount in the United States costs about 34,200 USD.[4]
References
edit- ^ a b c d e f g "Ayvakyt EPAR". European Medicines Agency (EMA). 20 July 2020. Archived from the original on 1 November 2020. Retrieved 29 September 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g h "Ayvakit- avapritinib tablet, film coated". DailyMed. 21 January 2020. Archived from the original on 27 September 2020. Retrieved 29 September 2020.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1013. ISBN 978-0857114105.
- ^ "Avapritinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 16 January 2022.